By separating genomics data from the predicted cellular source (such as stromal cell versus pancreatic tumour cell), Moffitt et al. have identified subtypes of pancreatic adenocarcinoma (PDAC). They characterized a basal-like subtype that has a worse prognosis than the subtype with activated stroma.